Biodegradation of the Antiretroviral Tenofovir Disoproxil by a Cyanobacteria/Bacterial Culture

被引:1
|
作者
Silva, Sandra Regina [1 ]
Souza-Silva, Gabriel [1 ]
Moreira, Carolina Paula de Souza [2 ]
Vasconcelos, Olivia Maria de Sousa Ribeiro [2 ]
Silveira, Micheline Rosa [1 ]
Barbosa, Francisco Antonio Rodrigues [1 ]
Magalhaes, Sergia Maria Starling [1 ]
Mol, Marcos Paulo Gomes [2 ]
机构
[1] Univ Fed Minas Gerais, Fac Farm, BR-30510010 Belo Horizonte, Brazil
[2] Fundacao Ezequiel Dias, Dept Pesquisa & Desenvolvimento, BR-30510010 Belo Horizonte, Brazil
关键词
drug; <italic>Microcystis novacekii</italic>; <italic>Pseudomonas pseudoalcaligenes</italic>; by-products; tenofovir isoproxil monoester; WASTE-WATER; SURFACE-WATER; CYANOBACTERIUM; ALGAL; PHARMACEUTICALS; MICROALGAE; FUMARATE; ADAPTATION; STABILITY; RESIDUES;
D O I
10.3390/toxics12100729
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Tenofovir disoproxil fumarate (TDF) is an antiretroviral drug extensively used by people living with HIV. The TDF molecule is hydrolysed in vivo and liberates tenofovir, the active part of the molecule. Tenofovir is a very stable drug and the discharge of its residues into the environment can potentially lead to risk for aquatic species. This study evaluated the TDF biodegradation and removal by cultures of Microcystis novacekii with the bacteria Pseudomonas pseudoalcaligenes. Concentrations of TDF of 12.5, 25.0, and 50.0 mg/L were used in this study. The process occurred in two stages. In the first 72 h, TDF was de-esterified, forming the tenofovir monoester intermediate by abiotic and enzymatic processes associated in an extracellular medium. In a second step, the monoester was removed from the culture medium by intracellular processes. The tenofovir or other by-products of TDF were not observed in the test conditions. At the end of the experiment, 88.7 to 94.1% of TDF and its monoester derivative were removed from the culture medium over 16 days. This process showed higher efficiency of TDF removal at the concentration of 25 mg/L. Tenofovir isoproxil monoester has partial antiviral activity and has shown to be persistent, maintaining a residual concentration after 16 days in the culture medium, therefore indicating the need to continue research on methods for total removal of this product from the aquatic environment.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
    Bukkems, Vera E.
    Smolders, Elise J.
    Jourdain, Gonzague
    Burger, David M.
    Colbers, Angela P.
    Cressey, Tim R.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (03): : 388 - 393
  • [12] Toxicological evaluation of antiretroviral Tenofovir Disoproxil Fumarate on the mollusk Biomphalaria glabrata and its hemocytes
    Souza-Silva, Gabriel
    Souza, Clessius Ribeiro
    Pereira, Cintia Aparecida de Jesus
    Lima, Walter dos Santos
    Mol, Marcos Paulo Gomes
    Silveira, Micheline Rosa
    SCIENCE OF THE TOTAL ENVIRONMENT, 2023, 891
  • [13] Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
    Lee, Sangmi
    Kim, Eunwoo
    Moon, Seol Ju
    Jung, Jina
    Lee, SeungHwan
    Yu, Kyung-Sang
    TRANSLATIONAL AND CLINICAL PHARMACOLOGY, 2021, 29 (01) : 45 - 52
  • [14] Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients
    Masquelier, Bernard
    Neau, Didier
    Boucher, Sebastien
    Lavignolle-Aurillac, Valerie
    Schrive, Marie-Helene
    Recordon-Pinson, Patricia
    Ragnaud, Jean-Marie
    Fleury, Herve
    ANTIVIRAL THERAPY, 2006, 11 (06) : 827 - 830
  • [15] Emtricitabine/tenofovir disoproxil fumarate
    不详
    Drugs in R & D, 2004, 5 (3) : 160 - 161
  • [16] TENOFOVIR DISOPROXIL FUMARATE-CONTAINING REGIMENS IN PREGNANCY: REPORT FROM THE ANTIRETROVIRAL PREGNANCY REGISTRY
    Brown, Robert S.
    Goodwin, Diane
    Peschell, Kenneth J.
    Zhang, Sherry
    Fagan, Elizabeth A.
    HEPATOLOGY, 2009, 50 (04) : 497A - 497A
  • [17] Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate
    Medland, Nicholas A.
    Chow, Eric P. F.
    Walker, Rowan G.
    Chen, Marcus
    Read, Tim R. H.
    Fairley, Christopher K.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2018, 29 (03) : 227 - 236
  • [18] Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection
    Tsai, Wan-Chen
    Hsu, Wei-Ting
    Liu, Wang-Da
    Sun, Hsin-Yun
    Chuang, Yu-Chung
    Huang, Yu-Shan
    Cheng, Aristine
    Lin, Kuan-Yin
    Huang, Yi-Chia
    Chen, Guan-Jhou
    Huang, Sung-Hsi
    Sheng, Wang-Huei
    Hsieh, Szu-Min
    Hung, Chien-Ching
    Chang, Shan-Chwen
    LIVER INTERNATIONAL, 2019, 39 (08) : 1408 - 1417
  • [19] Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate
    Medland, N. A.
    Chow, E. P. F.
    Walker, R. G.
    Chen, M.
    Read, T. H. R.
    Fairley, C. K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 71 - 71
  • [20] Emtricitabine/tenofovir disoproxil fumarate
    Pozniak, A
    DRUGS, 2004, 64 (18) : 2083 - 2084